Savara (SVRA) Gains from Investment Securities (2017 - 2024)

Savara's (SVRA) quarterly Gains from Investment Securities came in at $125000.0 in Q2 2024, up 495.24% on a QoQ basis from $21000.0 in Q1 2024.

Savara (SVRA) Gains from Investment Securities (2017 - 2024) Analysis & Trends

Savara (SVRA) has 4 years of Gains from Investment Securities data on file, last reported at $125000.0 in Q2 2024.

On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $125000.0 in Q2 2024; TTM through Jun 2024 was $146000.0, a N/A change from a year earlier, with the FY2019 full-year figure at $264000.0, down 0.75% from the prior year.
Gains from Investment Securities for Q2 2024 stood at $125000.0, up from $21000.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for SVRA reached as high as $125000.0 in Q2 2024 and fell as low as $21000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Savara	1.39 Bn	1.39 Bn	-

Download Data